Literature DB >> 25829389

Standardized outcome and reporting measures in pediatric head and neck lymphatic malformations.

Karthik Balakrishnan1, Nancy Bauman2, Robert H Chun3, David H Darrow4, J Fredrik Grimmer5, Jonathan A Perkins6, Gresham T Richter7, Jennifer J Shin8, Giridhar M Shivaram6, Douglas R Sidell9, Ravindhra G Elluru10.   

Abstract

OBJECTIVE: To develop general and site-specific treatment effect and outcome measures to standardize the reporting of head and neck lymphatic malformation (HNLM) treatments. STUDY
DESIGN: Consensus statement/expert opinion.
SETTING: Multiple tertiary academic institutions. SUBJECTS AND METHODS: The modified Delphi method is an iterative process of collecting expert opinions, refining opinions through discussion and feedback, statistically aggregating opinions, and using these aggregates to generate consensus opinion in the absence of other data. The modified Delphi method was used by a multi-institutional group of otolaryngology and interventional radiology experts in the field of vascular anomalies to formulate a list of recommended reporting outcomes for the study and treatment of head and neck lymphatic malformations.
RESULTS: Through 3 rounds of iteration, 10 expert panelists refined 98 proposed outcome measures and 9 outcome categories to a final consensus set of 50 recommended outcome measures in 3 global categories (general, demographics, and treatment complications) and 5 site-specific categories (orbit, oral cavity, pharynx, larynx, and neck).
CONCLUSIONS: We propose the first consensus set of standardized reporting measures for clinical and treatment outcomes in studies of HNLMs. Consistent outcome measures across future studies will facilitate comparison of treatment options and allow systematic review. We hope that these guidelines facilitate the design and reporting of subsequent HNLM studies. © American Academy of Otolaryngology-Head and Neck Surgery Foundation 2015.

Entities:  

Keywords:  Delphi technique; consensus; head and neck; lymphangioma; lymphatic malformation of face and neck; otolaryngology; outcome measures; pediatrics

Mesh:

Year:  2015        PMID: 25829389     DOI: 10.1177/0194599815577602

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  10 in total

1.  National Characteristics of Lymphatic Malformations in Children: Inpatient Estimates and Trends in the United States, 2000 to 2009.

Authors:  Jeffrey Cheng; Beiyu Liu; Alfredo E Farjat; Jonathan Routh
Journal:  J Pediatr Hematol Oncol       Date:  2018-04       Impact factor: 1.289

2.  A Radiologic Grading System for Assessing the Radiographic Outcome of Treatment in Lymphatic and Lymphatic-Venous Malformations of the Head and Neck.

Authors:  R De Leacy; D V Bageac; S Manna; B S Gershon; D Kirke; T Shigematsu; C Sinclair; D Chada; P Som; A Doshi; K Nael; A Berenstein
Journal:  AJNR Am J Neuroradiol       Date:  2021-08-26       Impact factor: 4.966

3.  A nomogram for predicting sclerotherapy response for treatment of lymphatic malformations in children.

Authors:  Zhiping Wu; Yun Zou; Ronghua Fu; Pingliang Jin; Hua Yuan
Journal:  Eur J Med Res       Date:  2022-10-21       Impact factor: 4.981

Review 4.  New Frontiers in Our Understanding of Lymphatic Malformations of the Head and Neck: Natural History and Basic Research.

Authors:  Jonathan A Perkins
Journal:  Otolaryngol Clin North Am       Date:  2018-02       Impact factor: 3.346

5.  Ethanolgel sclerotherapy of venous malformations improves health-related quality-of-life in adults and children - results of a prospective study.

Authors:  Walter A Wohlgemuth; Rene Müller-Wille; Veronika Teusch; Simone Hammer; Moritz Wildgruber; Wibke Uller
Journal:  Eur Radiol       Date:  2016-10-04       Impact factor: 5.315

Review 6.  The Role of Interventional Radiologists in the Treatment of Congenital Lymphatic Malformations.

Authors:  Julie Cronan; Anne E Gill; Jay H Shah; C Matthew Hawkins
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

7.  Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.

Authors:  Douglas R Sidell; Karthik Balakrishnan; Simon R Best; Karen Zur; Julia Buckingham; Alessandro De Alarcon; Fuad M Baroody; Jonathan M Bock; Emily F Boss; Charles M Bower; Paolo Campisi; Sharon F Chen; Jeffrey M Clarke; Kevin D Clarke; Alejandro Cocciaglia; Robin T Cotton; Giselle Cuestas; Kara L Davis; Victor H DeFago; Frederik G Dikkers; Ines Dossans; Walter Florez; Elizabeth Fox; Aaron D Friedman; Nazaneen Grant; Osama Hamdi; Norman D Hogikyan; Kaalan Johnson; Liane B Johnson; Romaine F Johnson; Peggy Kelly; Adam M Klein; Claire M Lawlor; Nicolas Leboulanger; Alejandro G Levy; Derek Lam; Greg R Licameli; Steve Long; David G Lott; Dayse Manrique; James Scott McMurray; Kara D Meister; Anna H Messner; Michael Mohr; Pamela Mudd; Anthony J Mortelliti; Daniel Novakovic; Julian Ongkasuwan; Shazia Peer; Krysztof Piersiala; Jeremy D Prager; Seth M Pransky; Diego Preciado; Tiffany Raynor; Rico N P M Rinkel; Hugo Rodriguez; Verónica P Rodríguez; John Russell; María Laura Scatolini; Patrick Scheffler; David F Smith; Lee P Smith; Marshall E Smith; Richard J H Smith; Abraham Sorom; Amalia Steinberg; John A Stith; Dana Thompson; Jerome W Thompson; Patricio Varela; David R White; Andre M Wineland; Christina J Yang; Carlton J Zdanski; Craig S Derkay
Journal:  Laryngoscope       Date:  2021-01-06       Impact factor: 2.970

Review 8.  Clinical application of molecular genetics in lymphatic malformations.

Authors:  Reema Padia; Kaitlyn Zenner; Randall Bly; James Bennett; Catherine Bull; Jonathan Perkins
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-01-12

9.  Medical Management of Vascular Anomalies.

Authors:  Reema Padia; Randall Bly; Catherine Bull; Amy E Geddis; Jonathan Perkins
Journal:  Curr Treat Options Pediatr       Date:  2018-04-27

10.  Refractory Head and Neck Lymphatic Malformation in Infants Treated With Sirolimus: A Case Series.

Authors:  Changhua Wu; Dan Song; Lei Guo; Liang Wang
Journal:  Front Oncol       Date:  2021-07-16       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.